Synthetic Cytotoxic Molecules, Drugs, Methods of Their Synthesis and Methods of Treatment
AssigneesThe Regents of the University of California, Universite de Montreal
InventorsAimee Edinger, Stephen Hanessian
Life of this patent
Estimating the term…
Abstract
Small molecules compounds and methods of their synthesis are provided. Formulations and medicaments are also provided that are directed to the treatment of disease, such as, for example, neoplasms, cancers, and other diseases. Therapeutics are also provided containing a therapeutically effective dose of one or more small molecule compounds, present either as pharmaceutically effective salt or in pure form, including, but not limited to, formulations for oral, intravenous, or intramuscular administration.
Claims39
A compound of formula
- wherein:
- R1 is a functional group selected from H, an alkyl chain, OH, (CH2)nOH, CHOH-alkyl, CHOH-alkyne, (CH2)nOR′, (CH2)nPO(OH)2 and esters thereof, CH═CHPO(OH)2 and esters thereof, (CH2CH2)nPO(OH)2 and esters thereof, and (CH2)nOPO(OH)2 and esters thereof, (CH2)nPO3 and esters thereof, where R′ is an alkyl, alkene or alkyne;
- R2 is an aliphatic chain (C6-C14);
- R3 is a mono-, di-, tri- or tetra-aromatic substituent comprising hydrogen, halogen, alkyl, alkoxy, azide (N3), ether, NO2, cyanide (CN), or a combination thereof;
- R4 is a functional group selected from H, alkyl including methyl (Me), tert-butyloxycarbonyl, or acyl;
- X− is an anion of the suitable acid;
- n is an independently selected integer selected from 1, 2, or 3;
- m is an independently selected integer selected from 0, 1 or 2;
- and comprising
- wherein the linking group connecting the phenyl ring to the azacycle may optionally include one or more functional groups selected from the following:
- a polar group in the alpha, beta or gamma position with regard to the azacycle selected from carbonyls (C═O), alcohols (CHOH), and alkoxys;
- and
- a cyclic carbon chain extending from the alpha, beta or gamma positions with regard to the azacycle back to the N of the azacycle;
- and a combination thereof.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A medicament for the treatment of a human disorder comprising:
- a pharmaceutical formulation containing a therapeutically effective amount of one or more small molecule compounds having the formula
- wherein:
- R1 is a functional group selected from H, an alkyl chain, OH, (CH2)nOH, CHOH-alkyl, CHOH-alkyne, (CH2)nOR', (CH2)nPO(OH)2 and esters thereof, CH═CHPO(OH)2 and esters thereof, (CH2CH2)nPO(OH)2 and esters thereof, and (CH2)nOPO(OH)2 and esters thereof, (CH2)nPO3 and esters thereof, where R′ is an alkyl, alkene or alkyne;
- R2 is an aliphatic chain (C6-C14);
- R3 is a mono-, di-, tri- or tetra-aromatic substituent comprising hydrogen, halogen, alkyl, alkoxy, azide (N3), ether, NO2, cyanide (CN), or a combination thereof;
- R4 is a functional group selected from H, alkyl including methyl (Me), tert-butyloxycarbonyl, or acyl;
- X− is an anion of the suitable acid;
- n is an independently selected integer selected from 1, 2, or 3;
- m is an independently selected integer selected from 0, 1 or 2;
- and comprising
- wherein the linking group connecting the phenyl ring to the azacycle may
- optionally include one or more functional groups selected from the following:
- a polar group in the alpha, beta or gamma position with regard to the azacycle selected from carbonyls (C═O), alcohols (CHOH), and alkoxys;
- and
- a cyclic carbon chain extending from the alpha, beta or gamma positions with regard to the azacycle back to the N of the azacycle,
- or a combination thereof.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A method of treatment of a human disorder comprising:
- administering a pharmaceutical formulation to a human subject, the pharmaceutical formulation containing a therapeutically effective amount of one or more small molecule compounds having the formula
- wherein:
- R1 is a functional group selected from H, an alkyl chain, OH, (CH2)nOH, CHOH-alkyl, CHOH-alkyne, (CH2)nOR', (CH2)nPO(OH)2 and esters thereof, CH═CHPO(OH)2 and esters thereof, (CH2CH2)nPO(OH)2 and esters thereof, and (CH2)nOPO(OH)2 and esters thereof, (CH2)nPO3 and esters thereof, where R′ is an alkyl, alkene or alkyne;
- R2 is an aliphatic chain (C6-C14);
- R3 is a mono-, di-, tri- or tetra-aromatic substituent comprising hydrogen, halogen, alkyl, alkoxy, azide (N3), ether, NO2, cyanide (CN), or a combination thereof;
- R4 is a functional group selected from H, alkyl including methyl (Me), tert-butyloxycarbonyl, or acyl;
- X− is an anion of the suitable acid;
- n is an independently selected integer selected from 1, 2, or 3;
- m is an independently selected integer selected from 0, 1 or 2;
- and comprising
- wherein the linking group connecting the phenyl ring to the azacycle may
- optionally include one or more functional groups selected from the following:
- a polar group in the alpha, beta or gamma position with regard to the azacycle selected from carbonyls (C═O), alcohols (CHOH) , and alkoxys;
- and
- a cyclic carbon chain extending from the alpha, beta or gamma positions with regard to the azacycle back to the N of the azacycle,
- or a combination thereof.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A compound having the formula:
Dependencies are inferred from the claim text.